- Home
- NEGG vs SLGL Comparison
NEGG vs SLGL Comparison
Compare NEGG & SLGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NEGG | SLGL |
|---|---|---|
| Founded | 2001 | 1997 |
| Country | United States | Israel |
| Employees | 714 | N/A |
| Industry | Other Specialty Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 222.7M | 218.9M |
| IPO Year | N/A | 2016 |
Fundamental Metrics
Financial Performance| Metric | NEGG | SLGL |
|---|---|---|
| Price | $9.78 | $67.53 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $152.50 |
| AVG Volume (30 Days) | 26.6K | ★ 29.4K |
| Earning Date | 08-27-2026 | 11-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.29 | $28.81 |
| 52 Week High | $96.29 | $97.97 |
Technical Indicators
Market Signals| Indicator | NEGG | SLGL |
|---|---|---|
| Relative Strength Index (RSI) | 33.89 | 49.26 |
| Support Level | N/A | $61.35 |
| Resistance Level | $20.11 | $81.22 |
| Average True Range (ATR) | 0.73 | 3.96 |
| MACD | 0.06 | 0.12 |
| Stochastic Oscillator | 19.58 | 58.11 |
Price Performance
Historical ComparisonAbout NEGG Newegg Commerce Inc.
Newegg Commerce Inc is an e-commerce company offering direct sales and an online marketplace platform for IT computer components, consumer electronics, entertainment, smart home, and gaming products, and provides certain third-party logistics services globally. Geographically, it operates in the United States, Canada, and the Rest of the world.
About SLGL Sol-Gel Technologies Ltd.
Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline includes SGT-610 (Patidegib Gel 2%), a new chemical entity hedgehog signaling pathway blocker, for the chronic use and prevention of new BCC in Gorlin syndrome patients, and the topical drug candidate SGT-210 for the treatment of Darier Disease and other rare keratosis-related indications such as PC, PPK and Olmsted. It generates the majority of its revenue from the United States.